Investigating the role of a specific receptor in heart and liver diseases
Tissue-specific roles of FXR in CVD and NASH
This study is looking at how a specific protein called FXR can help improve heart and liver health, especially for people dealing with high cholesterol and insulin resistance, by figuring out how it affects fat levels in the body and promotes healing.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-10908534 on NIH RePORTER |
What this research studies
This research focuses on understanding how the farnesoid X receptor (FXR) affects cardiovascular and liver diseases, particularly in conditions like hyperlipidemia and insulin resistance. The study aims to clarify the distinct roles of FXR in these diseases by examining its effects on cholesterol and triglyceride levels in the body. Researchers will explore how FXR can promote healing in the liver and reduce the buildup of harmful fatty deposits in blood vessels. By dissecting these tissue-specific activities, the research seeks to uncover new therapeutic targets for treating cardiovascular and liver conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with cardiovascular diseases or non-alcoholic steatohepatitis (NASH), particularly those experiencing hyperlipidemia or insulin resistance.
Not a fit: Patients with isolated liver diseases not related to metabolic conditions or those without cardiovascular risk factors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve heart and liver health for patients suffering from related diseases.
How similar studies have performed: Previous research has shown promising results with FXR agonists in reducing atherosclerosis and improving liver disease models, indicating a potential for success in this area.
Where this research is happening
La Jolla, United States
- University of California, San Diego — La Jolla, United States (Active)
Researchers
- Principal investigator: Evans, Ronald M — University of California, San Diego
- Study coordinator: Evans, Ronald M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.